Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
Mallinckrodt
Medtronic
Moodys

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Patent: 9,549,895

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,549,895
Title:Methods and compositions for preserving the viability of photoreceptor cells
Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous MCP-1, a MCP-1 antagonist, a substance capable of suppressing endogenous TNF-alpha, a TNF-alpha antagonist, a substance capable of suppressing endogenous IL-1 beta, an IL-1 beta antagonist, a substance capable of inducing endogenous bFGF, exogenous bFGF, a bFGF mimetic, and combinations thereof, to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.
Inventor(s): Nakazawa; Toru (Sendai Miyagi, JP)
Assignee: Massachusetts Eye and Ear Infirmary (Boston, MA)
Application Number:11/587,022
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,549,895
Patent Claims:see list of patent claims

Details for Patent 9,549,895

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL etanercept Injection 103795 2004-09-27 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL etanercept Injection 103795 2007-02-01 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL MINI etanercept Injection 103795 2017-09-14 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Try it Free 2024-04-23
Immunex Corporation ENBREL etanercept Injection 103795 2020-03-05 ⤷  Try it Free 2024-04-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.